Long-term Study of TAK-875

PHASE3CompletedINTERVENTIONAL
Enrollment

1,222

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Diabetes Mellitus
Interventions
DRUG

TAK-875

DRUG

TAK-875

Trial Locations (71)

Unknown

Nagoya

Chiba

Funabashi-shi

Katori-shi

Kisarazu-shi

Matsudo-shi

Matsuyama

Nihama-shi

Saijo-shi

Fukuoka

Kitakyushu-shi

Onga-gun

Annaka-shi

Takasaki-shi

Aki-gun

Hiroshima

Chitose-shi

Sapporo

Amagasaki-shi

Nishinomiya-shi

Mito

Naka

Tsuchiura-shi

Ushiku-shi

Sakade-shi

Izumi-shi

Kamakura-shi

Yamato-shi

Kochi

Suzaki-shi

Kumamoto

Minamata-shi

Uji-shi

Miyazaki

Matsumoto-shi

Nagasaki

Omura-shi

Ōita

Okayama

Izumisano

Kashiwara-shi

Osaka

Sakai-shi

Suita-shi

Toyonaka-shi

Saga

Fujimi-shi

Saitama-shi

Sayama-shi

Tokorozawa-shi

Ōtsu

Fujinomiya-shi

Shizuoka

Shimotsuga-gun

Shimotsuke-shi

Komatsu-shi

Bunkyo-ku

Chiyoda-ku

Chuo-ku

Hino-shi

Itabashi-ku

Katsushika-ku

Mitaka-shi

Nerima-ku

Ōta-ku

Shinjuku-ku

Sibuya-ku

Toyoshima-ku

Sanyoonoda-shi

Shimonoseki-shi

Ube-shi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01433406 - Long-term Study of TAK-875 | Biotech Hunter | Biotech Hunter